Selecta Biosciences raises $20 million

Selecta Biosciences said Wednesday it has secured $20 million in equity funding from new and all of Selecta’s existing investors. Including the $20 million, Selecta said it has obtained a total of $78.6 Million in funding to date. Investors include Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments. Selecta is a clinical stage biotechnology company that is developing a class of targeted antigen-specific immune therapies.


Sonendo raises $35 mln equity financing

Sonendo said Monday it completed an equity financing round of $35 million led by Meritech Capital Partners. New investor SEB Private Equity joined Fjord Ventures, OrbiMed Advisors and NeoMed Management in the round. Laguna Hills, Calif.-based Sonendo develops technology for the root canal therapy market.


Civitas Therapeutics scores $55 mln Series C

Civitas Therapeutics has closed $55 million in Series C funding. The investors included Adage Capital Management, OrbiMed Advisors, Partner Fund Management, Rock Springs Capital, Sofinnova Ventures, Canaan Partners, RA Capital and Wellington Management Company. Headquartered in Chelsea, Mass., Civitas Therapeutics is a biopharmaceutical company that focuses on developing treatments for Parkinson’s disease.


Bets pay off for venture funds in UC portfolio: VCJ

Last year saw several top performing funds in the University of California’s recent-vintage venture portfolio consolidate performance gains, as others continue to advanced, affiliate magazine Venture Capital Journal reported.

NEA leads Series B round for Loxo Oncology

Loxo Oncology has received $24 million in Series B financing. New Enterprise Associates led the round with participation from previous backers Aisling Capital and OrbiMed Advisors. In addition to the funding, Dr. M. James Barrett, a general partner at NEA, will join Loxo Oncology’s board of directors while Dr. Sara Nayeem, a principal at NEA, will also join the board as an observer. And, the firm has named Dr. Mikel Moyer as chief scientific officer. Loxo Oncology is a a biopharmaceutical company focused on targeted cancer therapies.

Otonomy scores $49 mln Series D funds

Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.

ProNAi Therapeutics raises Series D

ProNAi Therapeutics, a developer of novel nucleic acid therapeutics has closed an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital and included other new investors Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

SAGE Therapeutics nabs $38 mln Series C funds

SAGE Therapeutics has closed $38 million in Series C financing. Investors included OrbiMed Advisors, EcoR1 Capital Management, Foresite Capital Management, Third Rock Ventures and ARCH Venture Partners. Based in Cambridge, Mass., SAGE Therapeutics is a biopharmaceutical company focused on treating orphan central nervous system disorders.

Clementia Pharmaceuticals appoints

Clementia Pharmaceuticals, a privately held clinical stage biotechnology company has appointed three key executives with rare disease and orphan drug expertise: Donna Grogan, M.D., as chief medical officer, Jeff Packman as chief development officer and Eric Grinstead as chief commercial officer. The company is backed by OrbiMed Advisors and BDC Venture Capital.

Practice Fusion raises $70 mln from Kleiner Perkins, OrbiMed, Deerfield

Healthcare records management company Practice Fusion, which is aiming to grow its healthcare platform, has raised a $70 million Series D round of funding led by Kleiner Perkins Caufield & Byers and institutional investors OrbiMed Advisors and Deerfield Management Co. Existing investors, including Artis Ventures, also participated in the round, which brings the total amount raised by the San Francisco-based company to $134 million. As part of the funding, Beth Seidenberg, general partner at Kleiner Perkins, has joined the company board.

ViewRay Raises Fresh $15M for Its Medical Imaging Technology

ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget